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Adiponectin and Vulnerable Atherosclerotic Plaques
Ailin Barseghian, MD,* Dipika Gawande,† Mandeep Bajaj, MD‡
Irvine, California; and College Station and Houston, Texas
High-risk plaques that are vulnerable to rupture demonstrate distinct morphological characteristics. They are
differentiated from the lesions responsible for stable coronary artery disease by their large necrotic cores, thin-
inflamed fibrous caps, and positive remodeling. Adiponectin is an adipocytokine that is reduced in obesity and
type 2 diabetes. Hypoadiponectinemia has been associated with an increased risk of coronary artery disease
and acute coronary syndrome in several though not all studies. The involvement of adiponectin provides clues to
the inflammatory and atherogenic mechanisms associated with pathological coronary disease progression. (J Am
Coll Cardiol 2011;57:761–70) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.11.011Heart disease is the leading cause of death in the world (1).
Acute coronary events are a consequence of thrombotic
occlusions of coronary arteries, and thrombosis is believed to
be caused by plaque rupture in 75% of patients (2). Thus it
is consequently accepted as the critical event leading to acute
coronary syndrome (ACS) (3,4). These vulnerable plaques
are often large and consist of a necrotic core that forms a
significant portion of the plaque. Covered by a thin in-
flamed fibrous cap, the necrotic core is often associated with
intraplaque neovascularization and hemorrhage and adven-
titial vasa vasorum proliferation (5). Because vulnerability is
associated with inflammation, neovascularization, and the
necrotic core formation, it is prudent to investigate the medi-
ators of coronary artery disease and plaque vulnerability.
One important mediator of coronary artery disease
(CAD) progression is adiponectin. Adiponectin is a protein
secreted by adipose tissue (adipocytokine). A strong rela-
tionship has been demonstrated between plasma adiponec-
tin levels and both hepatic and peripheral tissue insulin
sensitivity in humans (6). One of the primary effects of
adiponectin in rodents is to increase fatty acid oxidation in
muscle, leading to a decrease in intracellular fatty acid
metabolites (i.e., long chain fatty acyl coenzyme A, diacyl-
glycerol, ceramides, and enhanced insulin signal transduc-
tion), resulting in an improvement in insulin sensitivity (7).
Hypoadiponectinemia in insulin-resistant states such as
obesity and type 2 diabetes is associated with increased
plasma levels of inflammatory markers such as C-reactive
protein (8,9) as well as an increased risk for CAD. Adi-
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induced activation of nuclear factor kappa-B–dependent
proinflammatory pathways, expression of endothelial adhe-
sion molecules, macrophage-to-foam cell transformation,
lipid accumulation in macrophages, and smooth muscle cell
proliferation. It remains to be investigated whether low
plasma adiponectin levels contribute directly or indirectly
(by aggravating the individual components of the metabolic
syndrome, including insulin resistance) to accelerated ath-
erosclerosis in patients with metabolic syndrome. Hypoadi-
ponectinemia has been associated with coronary lesion
complexity (10) and ACS (11). Adiponectin’s involvement
in the development of atherosclerosis appears to be more
related to the stability of atherosclerotic plaque rather than
the atherosclerotic burden (11,12). Thus adiponectin may
be involved in the pathogenesis of vulnerability of coronary
lesions.
Structure, Origin, and
Characteristics of Adiponectin
Adipocytes release hormones and cytokines that are func-
tionally diverse and include adiponectin as well as interleu-
kin (IL)-1, IL-6, IL-8, TNF-alpha, leptin, resistin, and
others (13,14). Adiponectin was originally discovered in the
mid 1990s and named Acrp30 (15), AdipoQ (16), apM1
(17), and GBP28 (18) by 4 independent groups. It is the
most abundant adipokine released by adipocytes in response
to extracellular stimuli and metabolic changes. Adiponectin
is predominately, but not exclusively, produced by adipose
tissue. Recent studies suggest that it is also synthesized and
secreted by human cardiomyocytes (19). The adiponectin
gene is located on chromosome 3q27 in humans (20) and
expresses a secretory protein that consists of 247 amino
acids including a carboxyl-terminal globular domain and an
amino-terminal collagen domain (21) and has a structure
similar to complement 1q (22) (Fig. 1).
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levels in Japanese non-obese subjects
have been approximated at 3 to 30
g/ml (23) with a significant reduc-
tion (50%) noted in obese subjects
(24). Although adiponectin is pro-
duced by adipocytes, plasma levels
actually are inversely proportional to
body mass index (BMI) and visceral
adiposity (14,24). Adiponectin exists
in plasma as complexes and binds by
its globular and collagen domain to
form 3 major oligomeric multimers:
a low-molecular-weight (LMW)
trimer, a middle-molecular-weight
(MMW) hexamer, and high-
molecular-weight (HMW) 12- to
18-multimer (25) (Fig. 1). A
fourth form found in the circula-
tion consists of a trimer bound to
albumin (Alb-LMW) (26).
MMW and LMW forms account
for 25% of the total adiponectin,
whereas HMW accounts for 50%
of the total adiponectin in humans
(26). Plasma levels of the HMW
multimer have stronger associa-
tions with insulin sensitivity than
the ratio of HMW multimer to
total adiponectin and total adi-
ponectin alone, suggesting that the
HMW multimer is the active form
(27). Thus measurements of spe-
cific multimeric forms may be
more valuable than simply measur-
ing total adiponectin levels. Two
adiponectin receptors have been
identified in mice (Fig. 1). Adi-
poR1 is abundantly expressed in
skeletal muscle and is also seen in
endothelial cells (28), cardiomyocytes (19,29), and pancreatic-
beta cells (30), whereas AdipoR2 is predominately in the liver
(31) and is also expressed in endothelial cells (32). These
eceptors are also expressed in human monocytes and macro-
hages (33). Adiponectin appears to mediate its actions via the
ctivation of the cyclic adenosine monophosphate (cAMP)–
ependent, AMP-activated protein kinase (AMPK), cycloox-
genase (COX)-2, and peroxisome proliferator-activated
eceptor-alpha pathways (34–37).
diponectin and ACS
ypoadiponectinemia has been associated with CAD and
CS in several (38–45) but not all studies (46–49) (Table 1).
Abbreviations
and Acronyms
ACS  acute coronary
syndrome(s)
AMP  adenosine
monophosphate
AMPK  adenosine
monophosphate-activated
protein kinase
BMI  body mass index
CAD  coronary artery
disease
cAMP  cyclic adenosine
monophosphate
COX  cyclooxygenase
CRP  C-reactive protein
eNOS  endothelial nitric
oxide synthase
HMW  high molecular
weight
IL  interleukin
LMW  low molecular
weight
MMP  matrix
metalloproteinase
MMW  middle molecular
weight
NO  nitric oxide
TCFA  thin-cap
fibroatheroma
TIMP  tissue inhibitor of
metalloproteinase
TNF  tumor necrosis
factor
TZD  thiazolidinedione
VEGF  vascular
endothelial growth factor
VH-IVUS  virtual histology
intravascular ultrasoundatients with plasma adiponectin levels 4.0 g/ml have a c-fold increase in the prevalence of angiographically deter-
ined CAD independent of other well-known risk factors,
ncluding diabetes mellitus, dyslipidemia, hypertension,
moking, and increased BMI (50). In a 10-year follow-up of
ealthy elderly patients, higher adiponectin levels were
ssociated with a lower risk of CAD independent of other
isk factors such as increased BMI and insulin resistance
51). Serum adiponectin levels are also inversely related to
he severity of CAD in nondiabetic patients (52,53). In a
tudy of 207 men, those with stable CAD and complex
oronary lesions had significantly lower plasma adiponectin
evels than those with stable CAD and simple lesions
54,55). Furthermore, those with multiple complex lesions
ad significantly lower levels of adiponectin than those with
ingle complex lesions in ACS, suggesting that adiponectin
s also an independent predictor of coronary lesion com-
lexity in ACS (54). In the event of ACS, plasma levels of
diponectin are significantly lower than in patients with
table CAD (54–56). The early phase of myocardial infarc-
ion in particular has been associated with a reduction in
diponectin levels (57). Higher levels of adiponectin have
een linked to decreased prevalence of CAD in both men
nd women and show a beneficial association with a lower
isk of nonfatal myocardial infarction in men without
re-existing CAD, although they have failed to predict
uture CAD events in women (Table 1, Rancho Bernardo
tudy) (49).
In addition to the direct relationship as above, there are
ultiple other markers of inflammation (which is an oblig-
tory component of plaque instability) that correlate with
diponectin. Results of numerous studies have established a
ositive association between C-reactive protein (CRP) lev-
ls and BMI (58), CAD (59), unstable angina (60), and
CS (61). Hypoadiponectinemia, which is associated with
uture risk of myocardial infarction in men without CAD
41), is negatively correlated with CRP levels in CAD
atients. Additionally, CRP has also been demonstrated to
ontribute to vascular inflammation by inhibiting nitric
xide (NO) production (62). The vasodilatory and protec-
ive effects of NO are impeded by such risk factors as
xidized low-density lipoproteins and CRP, which reduce
ndothelial NO synthase (eNOS) production (63,64). Di-
inished eNOS expression obstructs the ability of NO to
meliorate the vicious effects of inflammation. Adiponectin
as been shown to promote eNOS synthesis via the AMPK
athway (65), thus enhancing the anti-inflammatory effect
f NO. Adiponectin’s inhibition of CRP also results in
mproved NO synthesis by reducing downregulation of
NOS.
Vulnerable plaques, also referred to as thin-cap fibroathe-
oma (TCFA) (66), are the most common morphology of
upture-prone plaques that result in ACS occlusions
67,68). Most culprit lesions in ACS have a large quantity of
laque. Their vulnerability is defined as a relatively large
ecrotic lipid-laden core, intraplaque hemorrhage, and/or
alcification and abundant vasa vasorum. They are also
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February 15, 2011:761–70 Adiponectin and CADFigure 1 Antiatherosclerotic Effects of Adiponectin
Schematic representation of the effects of adiponectin on the endothelial cell and macrophage. Adipo  adiponectin receptor; AMPK  adenosine monophosphate-activated
protein kinase; cAMP  cyclic adenosine monophosphate; eNOS  endothelial nitric oxide synthase; HMW  high molecular weight; ICAM  intercellular adhesion molecule;
IKKB  IKB kinase; IL  interleukin; iNOS  inducible nitric oxide synthase; LMW  low molecular weight; MMP  matrix metalloproteinase; MMW  middle molecular weight;
NADPH  nicotinamide adenine dinucleotide phosphate; NF-KB  nuclear factor-kappa B; NO  nitric oxide; P13K  phosphatidylinositol 3’-kinase; PKA  protein kinase A;
RNA  ribonucleic acid; ROS  reactive oxygen species; SRA  class A scavenger receptor; TIMP  tissue inhibitor of metalloproteinase; TNF  tumor necrosis factor; VCAM
 vascular cell adhesion molecule.
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Adiponectin and CAD February 15, 2011:761–70covered by a thin, inflamed, fibrous cap that may fissure
(69,70). They often enlarge outward from the vessel lumen,
which is referred to as positive vessel remodeling (66,71,72).
In an effort to further evaluate adiponectin in stable CAD
and its association with plaque vulnerability, the TCFA
prevalence was identified using both virtual histology intra-
vascular ultrasound (VH-IVUS) and optical coherence to-
mography. Patients with TCFA identified by this method
had significantly lower adiponectin levels than patients
without TCFA. In fact, levels of adiponectin were signifi-
cantly lower in multivessel TCFA compared with those
with single-vessel TCFA. The authors concluded that
adiponectin is the strongest predictive factor of the presence
of TCFA and suggested that adiponectin can be used as a
biomarker for risk stratification in patients with vulnerable
plaques on the basis of these findings (73). Because the
degree of hypoadiponectinemia may be suggestive of the
extent of plaque vulnerability (54,55), it is pertinent to
determine adiponectin’s involvement in the components of
a vulnerable plaque.
Necrotic core. Necrotic core content is significantly corre-
lated with plaque size in patients with ACS. Culprit plaques
in patients with ACS have a larger amount of necrotic core
plaque than those without ACS (12). VH-IVUS is superior
for quantification of the plaque volume (74) and in detecting
the necrotic core. In patients without diabetes, decreased
adiponectin levels are associated with dyslipidemia; in-
creased plaque volume; lipid-rich, noncalcified coronary
plaque; and pathological intimal thickening, as evidenced by
IVUS (75). Adiponectin is believed to be involved in
regulating the development of necrotic core. A decrease in
adiponectin is associated with an increase in necrotic core
ratio in both culprit and nonculprit lesions in patients with
ACS as demonstrated by VH-IVUS, suggesting that lower
adiponectin levels reflect plaque vulnerability in this patient
population (12). Additionally, this association of decreased
plasma adiponectin level and increased necrotic core ratio
has not been demonstrated in patients with stable CAD
(12,73).
Neovascularization and intraplaque hemorrhage. Neovas-
cularization has a dual role in atherosclerosis (76). Although
it may be beneficial for its role in tissue hypoxia and
promotion of collateral growth in the prevention of ischemia
in tissues where circulation has been impaired, it is also
associated with nascent friable vessels involved in the
intraplaque hemorrhage that has shown to promote plaque
growth, instability, and rupture (66,68,77,78). Similarly,
adiponectin has demonstrated a dual role in the process of
neovascularization by displaying both pro- and antiangio-
genesis properties. Adiponectin’s ability to promote angio-
genesis (79) has been shown to be beneficial in its ability to
prevent ischemia. In adiponectin knock-out animals, exog-
enous administration of adiponectin at 30 min before
induction of ischemia, during ischemia, and 15 min after
reperfusion demonstrated a reduction in the size of infarct
(37). Neovascularization induced by transplanted endothe-Re T S S AC
S
H
P
F
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February 15, 2011:761–70 Adiponectin and CADlial progenitor cells has shown to be an effective treatment
for atherosclerosis and ischemic heart disease (80–82).
Physiological plasma concentrations of adiponectin promote
the migration of endothelial progenitor cells and contribute
to the process of new vessel formation (81). These results
suggest therapeutic neovascularization by adiponectin sup-
plementation may be useful in patients with ischemia heart
disease (81).
On the other hand, angiogenesis within the vessel wall is
associated with atherosclerotic lesions responsible for vas-
cular occlusions. The growing plaque and the increasing
oxygen requirements of the vessel wall promote vasa vaso-
rum proliferation. Increased proliferation of adventitial vasa
vasorum accompanies neovascularization and intraplaque
hemorrhage (82). Intraplaque hemorrhage has been associ-
ated with plaque vulnerability through the promotion of
plaque growth, instability, and rupture (66,69,83). Al-
though the exact mechanism of adiponectin in intraplaque
neovascularization remains unknown, its role in certain
elements of neovascularization has been elucidated. Adi-
ponectin’s protective role in plaque vulnerability is demon-
strated in the ability of adiponectin to directly inhibit
endothelial cell growth (84) and induce apoptosis in acti-
vated endothelial cells (85). Another key growth factor in
angiogenesis is vascular endothelial growth factor (VEGF).
VEGF is a potent stimulator of angiogenesis and functions
in endothelial proliferation, permeability, and survival (78).
VEGF has also been associated with plaque formation and
plaque destabilization (86). The application of various
concentrations of adiponectin to human coronary artery
endothelial cells demonstrated suppression of VEGF-
stimulated migration of human coronary artery endothe-
lial cells, suggesting a regulatory role of adiponectin in
vascular processes that have been associated with athero-
sclerosis (87).
Fibrous cap breakdown. Plaque vulnerability is further
enhanced by thinning and fissuring of the fibrous cap.
Macrophages and vascular smooth muscle cells promote the
local release of matrix metalloproteinases (MMP), which
degrade the supportive collagen, enabling fibrous cap insta-
bility and plaque rupture (88,89,90,91). MMP activity is
controlled by tissue inhibitor of metalloproteinase
(TIMP)-1, and adiponectin increases TIMP-1 expression
in human monocyte-derived macrophages (88,92). The
MMP-9/TIMP-1 ratio was demonstrated to be higher in
patients with ACS compared with those with stable angina
and in patients with complex lesions compared with those
with simple lesions (88). Given these findings, the MMP-9/
TIMP-1 ratio has been identified as an independent pre-
dictor of coronary plaque stability and CAD severity (88).
Adiponectin has an inverse relationship with MMP-9/
TIMP-1 ratio in patients with ACS (88). The inverse
relationship found between adiponectin and the MMP-9/
TIMP-1 ratio suggests that adiponectin modulates plaque
stability through the balance of this ratio (88). The tipped
balance between metalloproteinases and their inhibitorsresults in degradation of the fibrous cap and subsequent
plaque rupture (83,93).
Positive remodeling. In positive remodeling, lumen area is
preserved by outward expansion of the vessel wall despite
plaque grow (74). It has been suggested that plaques with
high lipid content and macrophage count are the plaques
involved in positive outward remodeling (71). IVUS studies
have shown that complex plaque anatomy and plaque
rupture occurs in the presence of marked outward remod-
eling more frequently (71) and is often associated with
plaque rupture in ACS (74). Associations between meta-
bolic factors and coronary plaque growth or remodeling
were elucidating using IVUS technology and compared with
coronary arteriography. It was suggested that plasma adi-
ponectin may be an independent risk factor for positive
vascular remodeling (Remodeling Index [RI] 1) in pa-
tients with stable angina after demonstrating significantly
lower levels of plasma adiponectin compared with those in
the negative remodeling group (vessel shrinkage, RI 1)
(94). Additionally, it has been demonstrated that adiponec-
tin directly modulates vascular remodeling as opposed to
systemically through its effects on glucose reduction and
lipid metabolism modulation in a study of mice controlled
for glucose and lipid profile (11,95,96).
Localization of Adiponectin
in Atherosclerotic Lesions
Adiponectin appears to have a protective effect on the
cardiovascular system via its anti-atherogenic and anti-
inflammatory effects (96,97), primarily through its actions
on endothelial cells and macrophages (65) (Fig. 1). Adi-
ponectin’s role has been identified in endothelial activation
(39), inflammatory factor propagation by adhesion mole-
cules expression (39), monocyte adhesion to vascular endo-
thelium (39) and migration into tunica intima, macrophage
activation (98), macrophage-to-foam cell transformation
(99,100), lipid accumulation in macrophages (99), smooth
muscle cell (SMC) proliferation (23,95), SMC migration
into the intima (23,95), and platelet aggregation (101)
(Table 2).
Endothelial dysfunction is generally accepted as the
initial step in atherogenesis and plays a critical role in the
development of atherosclerosis. The endothelium is a major
source of NO in the vasculature. NO plays a pivotal role in
endothelial dysfunction. In physiological amounts, NO
protects against vascular injury, inflammation, and throm-
bosis by prevention of leukocyte adhesion to the endothe-
lium, inhibition of vascular smooth muscle proliferation,
and limitation of platelet aggregation (63). Low levels of
adiponectin have been associated with increased NO inac-
tivation combined with decreased NO production, both of
which contribute to endothelial dysfunction (102). In in-
flammatory states, NO may react with reactive oxygen
species, such as nicotinamide adenine dinucleotide phos-
phate oxidase-induced superoxide, to produce highly reac-
NF-KB
o  vas
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Adiponectin and CAD February 15, 2011:761–70tive molecules (90,91). In vitro studies have demonstrated a
decrease in reactive oxygen species in the presence of
adiponectin (103,104). Hemeoxygenase has been identified
as a protective agent against oxidative insults and has been
shown to have a prolonged antidiabetic effect by working
synergistically with adiponectin (105,106).
After the initiation of endothelial dysfunction, vascular
inflammation characterized by increased adhesion molecule
expression via proinflammatory cytokines such as IL-1,
IL-8, and TNF-alpha can take place (63,107). Adiponectin
partakes in inflammatory factor propagation by adhesion
molecule expression (39). Inhibition of the TNF-induced
activation of nuclear factor kappa-B–dependent proinflam-
matory cAMP pathway (35,36) reduces the expression of
adhesion molecules such as vascular cell adhesion molecule-1,
intercellular adhesion molecule-1, and E selectin (39,108–110),
all of which have been detected in atherosclerotic lesions
(111). Local adiponectin to intima and adventitia of endo-
thelial wall suppresses the expression of vascular cell adhe-
sion molecule-1 and intercellular adhesion molecule-1 in
vascular walls, suggesting that adiponectin improves athero-
sclerosis in part by inhibition of the expression of these
inflammatory molecules in vivo (112). Adventitial fibro-
blasts play an important role in adventitial response to
vascular injury. Adventitial fibroblast proliferation, migra-
tion, and adventitial fibroblast transformation to myofibro-
blasts is inhibited by the administration of adiponectin via
the AdipoR1-AMPK-iNOS pathway, further demonstrat-
ing adiponectin’s protective role in the vasculature (113).
Recombinant adiponectin has been shown to attenuate
monocyte attachment to endothelial cells (35,39,99,114).
Upon adherence, monocytes migrate into the intima and
transform into macrophages that express class A scavenger
receptors that accumulate modified lipoproteins and form
lipid-laden macrophages known as foam cells. These foam
cells characterize the “fatty streak” and secrete proinflam-
matory cytokines. Adiponectin inhibits macrophage activa-
tion (98), macrophage-to-foam cell transformation
(99,100), and lipid accumulation in macrophages (92),
subsequently decreasing proinflammatory cytokines. The
Effect of Adiponectin on Atherosclerosis and the Vulnerable PlaqueTable 2 Effect of Adiponectin on Atherosclerosis and the Vulne
Mechanism
Endothelial
Dysfunction Monocyte Infiltration
M
Scav
Mediators 1 eNOS
1 NO
2 ROS
2 NF-KB
2 VCAM
2 ICAM
2 E-selectin
2 IL-8
2 Cla
rece
Histopathological
changes
2 Endothelial cell
activation
2 Endothelial cell
apoptosis
2 Monocyte adhesion
and migration
2 Acc
mo
lipo
2 Foa
eNOS endothelial nitric oxide synthase; ICAM intercellular adhesionmolecule; IL interleukin;
xygen species; SMC  smooth muscle cells; TIMP  tissue inhibitor of metalloproteinase; VCAMtransformation from a nonatherosclerotic intimal lesionwith intimal thickening with normal accumulation of SMCs
and “fatty streak” formation with accumulation of foam cells
to an atherosclerotic lesion with pathological intimal thick-
ening requires the combination of such SMCs in a lipid-rich
core. Adiponectin has been shown to decrease the progres-
sion of atherosclerosis by inhibiting both neointimal thick-
ening and SMC proliferation and migration to the intima in
vivo, suggesting a possible involvement in vascular remod-
eling (23,95,96). In cultured vascular smooth muscle cells,
adiponectin suppressed vascular smooth muscle cell prolif-
eration and migration via direct binding to platelet-derived
growth factor-BB (23). Adiponectin also inhibits platelet
aggregation and thrombus formation; however, the mecha-
nism of action remains unclear (101,115,116). Macrophages
add to the enlarging necrotic core when they succumb to
necrotic and apoptotic cell death (117). The HMW form of
adiponectin has been associated with suppression of endo-
thelial cell apoptosis (118). Adiponectin also promotes the
clearance of early apoptotic cells by macrophages (119).
Adiponectin as a Target
for Stabilization of Plaque
In vitro and animal studies demonstrate that administration
of adiponectin causes an increase in adiponectin plasma
levels and exerts protective effects on atherosclerosis pro-
gression (96,120). High levels of adiponectin can reduce
atherosclerosis by attenuating endothelial inflammation and
macrophage to foam cell transformation (100). Local adi-
ponectin to intima and adventitia of endothelial wall sup-
presses the expression of adhesion molecules in vascular
walls (112), and recombinant adiponectin decreases mono-
cyte attachment to endothelial cells (23).
Although direct adiponectin administration in humans
warrants further investigation, adiponectin levels can be
increased via indirect methods such as lifestyle modifica-
tions and pharmacological interventions (6,33,121–138)
(Table 3). Large reductions in weight (almost 14% reduc-
tion of BMI) by changes in lifestyle or after gastric bypass
have demonstrated an increase in adiponectin (135,137).
Plaque
hage
Receptor
ke
SMC
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Fibrous Cap
Attenuation Platelet Activation
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1 PDGF-BB
binding
1 TIMP-1 ?1 NO
?2sCD40L
tion of
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formation
2 SMC
proliferation
2 SMC
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2 Fibrous cap
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2 Platelet aggregation
2 Thrombus formation
nuclear factor kappa-B; NO nitric oxide; PDGF platelet-derived growth factor; ROS reactive
cular cell adhesion molecule.rable
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enger
Upta
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ptors
umula
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protein
m cellThiazolidinediones (TZDs), which act through peroxisome
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February 15, 2011:761–70 Adiponectin and CADproliferator activator receptors gamma, also increase serum
adiponectin levels (6,133,134). The increase is almost 3-fold
in diabetic patients (6). A meta-analysis of 19 studies
confirmed an increase of endogenous adiponectin levels
with TZD use (133). Recently, it has also been suggested
that pioglitazone, a TZD, may stabilize coronary plaque
contents by increasing adiponectin levels. In a study of
diabetic subjects, pioglitazone therapy was not only corre-
lated with an increase in adiponectin levels, but also with a
reduction in the necrotic-core component in plaques based
on VH-IVUS analysis (134). Although promising, knowl-
edge of adiponectin’s actions remains incomplete and cre-
ates a barrier against the possible future therapeutic devel-
opment of adiponectin.
Conclusions
Adiponectin plays a significant role in CAD and plaque
vulnerability, as demonstrated by its association with the
stepwise progression of atherogenesis and, more impor-
tantly, the components of plaque vulnerability. However,
most of the available data are epidemiological in nature and
do not prove causal association (46,49,139–142). As more
details of adiponectin’s antiatherogenic, anti-inflammatory,
and anti-remodeling properties continue to emerge, meth-
ods of increasing adiponectin may become a promising new
therapy for the prevention and treatment of CAD and ACS.
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